Erratum: EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging (American Journal of Gastroenterology (2013) 108 (1891-1900) DOI: 10.1038/ajg.2013.354);Emerging biomarkers in inflammatory bowel disease (embark) study identifies fecal calprotectin, serum mmp9, and serum il-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging

American Journal of Gastroenterology

Volumn 108, Issue 12, 2013, Pages 1891-1900

  Faubion, William A ^a   Fletcher, Joel G ^a   O'Byrne, Sharon ^b   Feagan, Brian G ^c   De Villiers, Willem Js ^d   Salzberg, Bruce ^e   Plevy, Scott ^f   Proctor, Deborah D ^g   Valentine, John F ^h   Higgins, Peter D ⁱ   Harris, Jeffrey M ^b   Diehl, Lauri ^b   Wright, Lilyan ^b   Tew, Gaik Wei ^b   Luca, Diana ^b   Basu, Karen ^b   Keir, Mary E ^b  

^a MAYO CLINIC   (United States)

^b GENENTECH INC   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF KENTUCKY   (United States)

^e Atlanta Gastroenterology Specialists PC   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; GELATINASE B; INTERLEUKIN 22;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CROSS-SECTIONAL STUDY; ENTERITIS; FECES ANALYSIS; FEMALE; GASTROENTEROLOGIST; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 84889644856     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.69     Document Type: Erratum

References (44)

1. Samuel S, Bruining DH, Loftus EV Jr et al. Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol 2012; 10 : 1253-9.
2. Siddiki HA, Fidler JL, Fletcher JG et al. Prospective comparison of stateof- the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009; 193 : 113-21.
3. Siddiki H, Fletcher JG, Hara AK et al. Validation of a lower radiation computed tomography enterography imaging protocol to detect Crohn's disease in the small bowel. Inflamm Bowel Dis 2011; 17 : 778-86.
4. Solem CA, Loftus EV Jr, Fletcher JG et al. Small-bowel imaging in Crohn's disease: A prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008; 68 : 255-66.
5. Lee SS, Kim AY, Yang SK et al. Crohn disease of the small bowel: Comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009; 251 : 751-61.
6. Colombel JF, Solem CA, Sandborn WJ et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: Correlation with endoscopic severity and C reactive protein. Gut 2006; 55 : 1561-7.
7. Bodily KD, Fletcher JG, Solem CA et al. Crohn Disease: Mural attenuation and thickness at contrast-enhanced CT Enterography - correlation with endoscopic and histologic findings of inflammation. Radiology 2006; 238 : 505-16.
8. Voderholzer WA, Beinhoelzl J, Rogalla P et al. Small bowel involvement in Crohn's disease: A prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut 2005; 54 : 369-73.
9. Solem CA, Loftus EV Jr, Tremaine WJ et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11 : 707-12.
10. Higgins PD, Caoili E, Zimmermann M et al.computed tomographic enterography adds information to clinical management in small bowel Crohn's disease. Inflamm Bowel Dis 2007; 13 : 262-8.
11. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1 : 514.
12. Daperno M, DHaens G, Van Assche G et al. Development and validation of a new, simplifi ed endoscopic activity score for Crohn's disease: The SES-CD. Gastrointest Endosc 2004; 60 : 505-12.
13. Booya F, Akram S, Fletcher JG et al. CT enterography and fistulizing Crohn's disease: Clinical benefi t and radiographic findings. Abdom Imaging 2009; 34 : 467-75.
14. Noble CL, Abbas AR, Cornelius J et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis. Gut 2008; 57 : 1398-405.
15. Noble CL, Abbas AR, Lees CW et al. Characterization of intestinal gene expression profi les in Crohn's disease by genome-wide microarray analysis. Inflamm Bowel Dis 2010; 16 : 1717-28.
16. Zissis M, Afroudakis A, Galanopoulos G et al. B2 microglobulin: Is it a reliable marker of activity in inflammatory bowel disease Am J Gastroenterol 2001; 96 : 2177-83.
17. Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin- 1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994; 35 : 77-83.
18. Nielsen OH, Kirman I, Johnson K et al. The circulating common gamma chain (CD132) in inflammatory bowel disease. Am J Gastroenterol 1998; 93 : 323-8.
19. Wolk K, Witte E, Hoff mann U et al. IL-22 induces lipopolysaccharide- binding protein in hepatocytes: A potential systemic role of IL-22 in Crohn's disease. J Immunol 2007; 178 : 5973-81.
20. von Lampe B, Barthel B, Coupland SE et al. Diff erential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47 : 63-73.
21. Costa F, Mumolo MG, Bellini M et al. Role of faecal calprotectin as noninvasive marker of intestinal inflammation. Dig Liver Dis 2003; 35 : 642-7.
22. Walker TR, Land ML, Kartashov A et al. Fecal lactoferrin is a sensitive and specifi c marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44 : 414-22.
23. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: Current practices and recent advances. Transl Res 2012; 159 : 313-25.
24. Faubion WA, Fletcher JG, De Villiers W et al. Assessing Crohn's disease inflammatory biomarker diagnostic accuracy using ileocolonoscopy or a combined ileocolonoscopy-CTE score in the EMBARK study. Gastroenterology 2012; 142 : S-658.
25. Rahier JF, Pariente B, Colombel JF. Skipping Crohn's disease: When ileocolonoscopy is not enough. Clin Gastroenterol Hepatol 2012; 10 : 1260-1.
26. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34 : 50-4.
27. Langhorst J, Elsenbruch S, Koelzer J et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103 : 162-9.
28. Sipponen T, Savilahti E, Kolho KL et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14 : 40-6.
29. DHaens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18 : 2218-24.
30. Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61 : 1693-700.
31. Feagan BG, Rutgeerts P, Sands BE et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo-controlled, doubleblind, multicenter phase 3 trial. Gastroenterology 2012; 142 : S-160.
32. Sipponen T, Karkkainen P, Savilahti E et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol ther 2008; 28 : 1221-9.
33. Sipponen T, Bjorkesten CG, Farkkila M et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 2010; 45 : 325-31.
34. De Vos M, Dewit O, DHaens G et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis. J Crohns Colitis 2012; 6 : 557-62.
35. Jones J, Loftus EV Jr, Panaccione R et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6 : 1218-24.
36. Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105 : 162-9.
37. Altadill A, Eiro N, Gonzalez LO et al.comparative analysis of the expression of metalloproteases and their inhibitors in resected crohn's disease and complicated diverticular disease. Inflamm Bowel Dis 2012; 18 : 120-30.
38. Lakatos G, Sipos F, Miheller P et al. The behavior of matrix metalloproteinase- 9 in lymphocytic colitis, collagenous colitis and ulcerative colitis. Pathol Oncol Res 2012; 18 : 85-91.
39. Makitalo L, Sipponen T, Karkkainen P et al. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profi le in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis 2009; 24 : 1157-67.
40. Gao Q, Meijer MJ, Schluter UG et al. infliximab treatment infl uences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 2007; 13 : 693-702.
41. Ouyang W, Rutz S, Crellin NK et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29 : 71-109.
42. Geremia A, Arancibia-Carcamo CV, Fleming MP et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011; 208 : 1127-33.
43. Brand S, Beigel F, Olszak T et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290 : G827-38.
44. Ciccia F, Accardo-Palumbo A, Alessandro R et al. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum 2012; 64 : 1869-78